Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | METAP2 | P50579 | 16/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305455 | 0.87 | HDAC8 (0.50) | HDAC8HDAC6METAP2HSD11B1MEN1 | |
| SCHEMBL30577920 | 0.82 | HDAC8 (0.49) | HDAC8HDAC6METAP2HSD11B1MEN1 | |
| SCHEMBL14817519 | 0.82 | METAP2 (0.51) | HDAC8HDAC6METAP2HSD11B1 | |
| SCHEMBL10202312 | 0.79 | METAP2 (0.48) | HDAC8HDAC6METAP2HSD11B1 | |
| SCHEMBL13926133 | 0.79 | METAP2 (0.48) | HDAC8HDAC6METAP2HSD11B1 | |
| SCHEMBL12251987 | 0.79 | METAP2 (0.54) | HDAC8HDAC6METAP2 | |
| SCHEMBL14411952 | 0.77 | LMNA (0.40) | METAP2HSD11B1NPC1RAB9A | |
| SCHEMBL27081933 | 0.77 | HDAC8 (0.44) | HDAC8HDAC6METAP2HSD11B1MEN1 | |
| SCHEMBL6410939 | 0.76 | HSD11B1 (0.53) | HDAC8HDAC6METAP2HSD11B1MEN1 | |
| SCHEMBL10409201 | 0.76 | MEN1 (0.54) | HDAC8HDAC6METAP2HSD11B1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | claimed |
| WO-2013044361-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2013-04-04 | — | — | WO | disclosed |
| WO-2011127567-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | HDAC8 1907/4885HDAC6 671/4885METAP2 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.